Moderna, Inc. MRNA

Company Overview

Moderna, Inc. is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) technology. The company operates primarily within the biopharmaceutical and life sciences industries, leveraging its proprietary mRNA platform to design therapies and vaccines that instruct cells to produce proteins for disease prevention or treatment. Moderna’s core revenue historically has been driven by its COVID-19 vaccine, Spikevax, with an expanding pipeline targeting infectious diseases, oncology, cardiovascular disease, and rare genetic disorders.

Founded in 2010, Moderna was established to commercialize advances in mRNA science that enable rapid drug development and scalable manufacturing. The company evolved from a research-stage biotech into a commercial-stage pharmaceutical company following the global deployment of its COVID-19 vaccine beginning in 2020. Moderna positions itself as a platform company, emphasizing speed, flexibility, and digital integration across research, development, and manufacturing as key strategic advantages.